statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atai Life Sciences ( NASDAQ:ATAI ) Full Year 2023 Results Key Financial Results Net loss: US$40.2m (loss narrowed by...

Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato Initial BPL-003...

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical...

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

The Next Great Biotech Boom Has Arrived The Next Great Biotech Boom Has Arrived PR Newswire LONDON, March 19, 2024 FN Media Group Presents GlobalInvestmentDaily.com Market Commentary LONDON, March...

The Next Great Biotech Boom Has Arrived

The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai's proprietary, optimized oral transmucosal formulation of DMTVLS-01 is being...

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ( atai ), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ( atai or Company ) today announced that Anne Johnson, the Company's interim Chief Financial Officer since...

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder...

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo...

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and a range of exploratory pharmacodynamic (PD...

atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Volume	842,720.00
52-Wk High	$2.85
52-Wk Low	$1.03

ATAI ATAI Life Sciences N.V.

About

Feed

News

Earnings

Fundamentals